Noble Financial Boosts Earnings Estimates for GeoVax Labs

GeoVax Labs Inc. (NASDAQ:GOVX) – Research analysts at Noble Financial raised their Q3 2026 earnings estimates for GeoVax Labs in a research note issued to investors on Wednesday, July 29th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings per share of ($1.09) for the quarter, up from their prior forecast of ($3.28). The consensus estimate for GeoVax Labs’ current full-year earnings is ($8.69) per share. Noble Financial also issued estimates for GeoVax Labs’ Q4 2026 earnings at ($1.20) EPS, FY2026 earnings at ($5.14) EPS and FY2027 earnings at ($2.64) EPS.

A number of other brokerages have also recently issued reports on GOVX. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a report on Friday, July 17th. Finally, D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a research report on Thursday, April 16th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, GeoVax Labs has a consensus rating of “Reduce” and an average price target of $150.00.

GeoVax Labs Trading Down 0.6%

GOVX opened at $0.69 on Friday. The company has a 50 day moving average of $1.43 and a 200 day moving average of $1.74. The company has a market cap of $2.41 million, a PE ratio of -0.04 and a beta of 3.68. GeoVax Labs has a 12 month low of $0.64 and a 12 month high of $20.00.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Monday, July 27th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.16) by $1.19.

Hedge Funds Weigh In On GeoVax Labs

Several hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in GeoVax Labs during the 1st quarter worth approximately $27,000. HRT Financial LP bought a new position in GeoVax Labs in the 4th quarter valued at $31,000. Renaissance Technologies LLC bought a new position in GeoVax Labs in the 4th quarter valued at $104,000. Finally, Armistice Capital LLC purchased a new position in shares of GeoVax Labs during the 3rd quarter valued at $253,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.